Trial watch: dendritic cell vaccination for cancer immunotherapy. Review uri icon

Overview

abstract

  • Dendritic- cells (DCs) have received considerable attention as potential targets for the development of anticancer vaccines. DC-based anticancer vaccination relies on patient-derived DCs pulsed with a source of tumor-associated antigens (TAAs) in the context of standardized maturation-cocktails, followed by their reinfusion. Extensive evidence has confirmed that DC-based vaccines can generate TAA-specific, cytotoxic T cells. Nonetheless, clinical efficacy of DC-based vaccines remains suboptimal, reflecting the widespread immunosuppression within tumors. Thus, clinical interest is being refocused on DC-based vaccines as combinatorial partners for T cell-targeting immunotherapies. Here, we summarize the most recent preclinical/clinical development of anticancer DC vaccination and discuss future perspectives for DC-based vaccines in immuno-oncology.

publication date

  • July 18, 2019

Identity

PubMed Central ID

  • PMC6791419

Scopus Document Identifier

  • 85072034344

Digital Object Identifier (DOI)

  • 10.3389/fimmu.2019.00824

PubMed ID

  • 31646087

Additional Document Info

volume

  • 8

issue

  • 11